New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:05 EDTSLXPSalix price target raised to $150 from $125 at Brean Capital
Brean Capital raised its price target on Salix to $150 from $125 to reflect the tax inversion benefits of its Cosmo acquisition. The firm also cited the addition of patents from Cosmo and positive TARGET 3 data for Xifaxan for use in irritable bowel syndrome and keeps its Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SLXP

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use